Bristol-Myers Squibb

YTD

ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.

CEO

Christopher S. Boerner

CEOChristopher S. Boerner

Employees

34,100

Employees34,100

Headquarters

Princeton, New Jersey

HeadquartersPrinceton, New Jersey

Founded

1933

Founded1933

Employees

34,100

Employees34,100

BMY Key Statistics

Market cap

95.75B

Market cap95.75B

Price-Earnings ratio

17.66

Price-Earnings ratio17.66

Dividend yield

5.19%

Dividend yield5.19%

Average volume

13.13M

Average volume13.13M

High today

$47.82

High today$47.82

Low today

$46.47

Low today$46.47

Open price

$46.65

Open price$46.65

Volume

9.84M

Volume9.84M

52 Week high

$63.33

52 Week high$63.33

52 Week low

$39.71

52 Week low$39.71

BMY News

TipRanks 6d

Bristol-Myers Squibb’s Ozanimod Study: A Potential Game-Changer for Ulcerative Colitis Treatment

Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premi...

TipRanks 6d

Pfizer and Bristol-Myers Squibb’s Promising Study on Multiple Myeloma Treatment

Bristol-Myers Squibb Company ((BMY)), Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advanta...

TipRanks 6d

Bristol-Myers Squibb’s MORAb-202 Study: A Potential Game-Changer in Cancer Treatment

Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premi...

Analyst ratings

71%

of 28 ratings

Buy

25%

Hold

71.4%

Sell

3.6%

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.